U.S. Markets closed

Stemline Therapeutics reports 2Q loss

NEW YORK (AP) _ Stemline Therapeutics Inc. (STML) on Tuesday reported a loss of $15.5 million in its second quarter.

On a per-share basis, the New York-based company said it had a loss of 66 cents.

The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 48 cents per share.

The biopharmaceutical company posted revenue of $299,400 in the period. Its adjusted revenue was $299,000.

Stemline Therapeutics shares have declined 17 percent since the beginning of the year. The stock has climbed 18 percent in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on STML at https://www.zacks.com/ap/STML

_____

Keywords: Stemline Therapeutics, Earnings Report